Stock Price

A Chinese energy firm is pushing ahead with a Saudi factory, a high-stakes wager that post-conflict rebuilding will outweigh profound geopolitical risks.

After a lengthy legal battle, BGIN Blockchain has recovered 5,325 mining rigs, a move that highlights industry risks and powers its pivot to self-mining.

Payments firm REPAY is doubling down on its $372M KUBRA acquisition, but activist investor Veradace Partners is calling for the deal to be scrapped.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

The passing of Gordon Bowerman, Yangarra's chairman for over two decades, leaves a legacy of growth and a critical question of succession for the company.

TMSH announces a transformative eyewear deal for its subsidiary, but research reveals the vintage brand's focus was apparel just weeks ago.

Mobile game maker DarkIris pivots to an AI-first strategy, launching an R&D hub in Singapore to build a pan-entertainment AGI content platform.

As Crocs sets its Q1 earnings call, all eyes are on the struggling HEYDUDE brand, contrasting with the core brand's strong international performance.

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

As online reviews face a crisis of trust, a Bay Area company doubles down on a physical directory, betting that verified quality is worth its weight in paper.

A legal battle erupts in Nevada as Getchell Gold Corp. defends its Fondaway Canyon project against a rival's claim on its most valuable ground.

Facing Nasdaq delisting, Chinese IT firm Hitek Global enacts a massive reverse stock split. Is this a strategic reset or a desperate last stand for survival?

Sieve Capital launches a public campaign against Americold Chairman Mark Patterson, citing a -50% return and a history of poor corporate governance.

The massive C$5.15 billion deal transforming Plains into a crude oil pure-play and Keyera into an NGL giant faces a delay amid a Competition Bureau review.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

NIP Group faces a delisting threat after its stock plunged. With 180 days to recover, can its unique esports and Bitcoin model win back investors?

Allspring's closed-end funds offer tempting yields, but tiny shifts in their monthly payouts reveal a complex story of risk, return, and capital erosion.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

Cocoa prices are falling, but your chocolate bar costs more. Discover why consumers are embracing this shift by reaching for premium, pricier treats.

Rithm Capital declared its 52nd straight dividend. Is its high yield and analyst praise enough to overcome recent stock woes and market skepticism?